Skip to content

Effect of an adjuvant on the properties of muscle relaxent

"Evaluation of the Effects of Rocuronium Bromide on its neuromuscular Blocking Characteristics by the Addition of 7.5% Sodium Bicarbonate" - RACE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/04/005729
Enrollment
80
Registered
2015-04-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Undergoing elective surgery of any kind under GA

Interventions

Intervention1: 50mg rocuronium mixed with 7.5% sodium bicarbonate: Intravenous rocuronium produces intense discomfort at the site of injection hence leading to limb movements. Various strategies and d

Sponsors

Acharya Shri Chander College of Medical Sciences and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 80 ASA physical status I or II patients, scheduled to undergo elective surgery with general anaesthesia were enrolled for the study.

Exclusion criteria

Exclusion criteria: Patients with ASA physical status III or greater, uncontrolled hypertension, coronary heart disease, neuromuscular disorders, pregnancy, anticipated difficult airway, body weight more than 20% of ideal body weight and those who were on any drug known or suspected of interfering with neuromuscular dysfunction, were not included in the study.

Design outcomes

Primary

MeasureTime frame
Shorter onset time and increased duration of action of rocuroniumTimepoint: Neuromuscular monitoring was done every 10 seconds, till we obtained the absence of all the four twitch responses out of the TOF sequence. During maintenance, neuromuscular monitoring was repeated every 5 minutes and the maintenance dose of relaxant was given when T2 response was recorded out of the TOF sequence.

Secondary

MeasureTime frame
Alleviation of pain on intravenous injection of rocuronium.Timepoint: At the time of administering intravenous rocuronium.

Countries

India

Contacts

Public ContactDr Jyoti Bedi

Acharya Shri Chander College of Medical Sciences and Hospital

drkmahotra@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026